KY-0601

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameKY-0601

Drug Alias NameKY-0601

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-CD276Anti-Hepatocyte growth factor receptor

TargetsHepatocyte growth factor receptorCD276 antigen

Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursColorectal NeoplasmsEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A